8-K: Unicycive Therapeutics Announces Positive Results from Oxylanthanum Carbonate Pivotal Clinical Trial, NDA Submission Expected in Q3 2024

Unicycive Therapeutics reports successful results from its OLC pivotal trial, demonstrating favorable tolerability and safety, paving the way for a New Drug Application submission in Q3 2024.

Summary

• Unicycive Therapeutics has announced positive results from its Oxylanthanum Carbonate (OLC) UNI-OLC-201 pivotal clinical trial.
• The trial focused on the tolerability and safety of OLC in patients with chronic kidney disease (CKD) undergoing hemodialysis.
• The study successfully met both its primary and secondary endpoints.
• The primary endpoint, which was the rate of discontinuations due to treatment-related adverse events, was low at 1.4% in the Evaluable Population (n=71) and 3.5% in the Safety Population (n=86).
• The secondary endpoint, assessing safety, showed that most treatment-related adverse events were mild to moderate, with no treatment-related serious adverse events reported.
• While not designed to evaluate efficacy, 90% of patients achieved target phosphate levels of 5.5 mg/dL at the end of titration with OLC.
• The company anticipates submitting a New Drug Application (NDA) to the FDA in Q3 2024 using the 505(b)(2) regulatory pathway.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a clear path to regulatory approval, suggesting a strong outlook for the company. The low adverse event rate and high phosphate control are particularly encouraging.

Positives

• The trial showed a low rate of discontinuations due to adverse events, with only 6% of patients discontinuing overall.
• The treatment-related discontinuation rate was particularly low at 1.4% in the Evaluable Population.
• Most treatment-related adverse events were mild to moderate, and there were no treatment-related serious adverse events.
• OLC demonstrated effective phosphate control, with 90% of patients achieving target levels at the end of titration.
• The study was well-received by investigators and patients, leading to over-enrollment.
• OLC has a potential best-in-class profile with a lower pill burden compared to other phosphate binders.

Negatives

• Some patients experienced treatment-related adverse events such as diarrhea (9%) and vomiting (6%).
• While most adverse events were mild to moderate, two were reported as severe.
• The study was not designed to evaluate efficacy, so the phosphate control data is not a primary endpoint.

Risks

• The topline data from the OLC pivotal trial is preliminary and subject to change based on further detailed analysis.
• Clinical trials involve a lengthy and expensive process with an uncertain outcome.
• There are risks related to business interruptions, dependence on key personnel, and substantial competition.
• The company faces uncertainties of patent protection and litigation.
• There are risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company anticipates submitting a New Drug Application (NDA) to the FDA in Q3 2024 and expects potential FDA approval by mid-year 2025.

Management Comments

• Shalabh Gupta, MD, Chief Executive Officer of Unicycive, stated that the results demonstrate extremely promising tolerability results in real-world dialysis patients.
• Dr. Gupta believes these favorable results confirm the tolerability of OLC and are the final data component needed to support the NDA submission.
• Pablo Pergola, MD, PhD, principal investigator for the UNI-OLC-201 trial, expressed encouragement by the results and believes OLC could have a meaningful impact on the care of CKD patients on dialysis.

Industry Context

The announcement is significant as it addresses the unmet need for better phosphate control in dialysis patients, where approximately 40% are unable to achieve adequate serum phosphate control. The market for hyperphosphatemia treatments is substantial, with a global opportunity exceeding $2.5 billion.

Comparison to Industry Standards

• The discontinuation rate due to adverse events in the OLC trial was 6%, which compares favorably to the 14% discontinuation rate reported for Fosrenol in its FDA-approved Package Insert.
• The treatment-related adverse events of diarrhea (9%) and vomiting (6%) are consistent with other phosphate binders on the market, but the overall safety profile of OLC appears to be competitive.
• The study's phosphate control results, with 90% of patients achieving target levels at the end of titration, are promising compared to historical data from the US-DOPPS cohort, which showed that a significant percentage of patients do not achieve target phosphate levels.
• The company is using the 505(b)(2) regulatory pathway, which allows them to leverage existing data on Fosrenol, potentially speeding up the approval process.

Stakeholder Impact

• Shareholders are likely to react positively to the successful trial results and the anticipated NDA submission.
• Patients with chronic kidney disease on dialysis may benefit from a new treatment option with potentially better tolerability and lower pill burden.
• Physicians may have a new tool to help patients achieve better phosphate control.
• Employees may be positively impacted by the company's progress and potential growth.

Next Steps

• The company plans to submit a New Drug Application (NDA) to the FDA in Q3 2024.
• The company will continue to assess the pharmacokinetics from the trial and include the final data in the NDA package.
• The company anticipates potential FDA approval by mid-year 2025.
• The company will build out its commercial infrastructure in preparation for potential product launch.

Key Dates

Keywords

Oxylanthanum Carbonate, OLC, Hyperphosphatemia, Chronic Kidney Disease, CKD, Hemodialysis, Phosphate Binder, Clinical Trial, NDA, FDA, Tolerability, Safety